Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Samuraciclib + Elacestrant in HR+/HER2- Metastatic Breast Cancer
2023-503846-30-00Phase 2Completed
- Sponsor
- Carrick Therapeutics
- Start
- Sep 2023
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of samuraciclib and elacestrant in breast cancer, sponsored by Carrick Therapeutics. Primary endpoints: Phase 1b: Identification of Phase 2 expansion dose level and Phase 2: Progression-free survival (PFS). Started Sep 2023; status: completed.
02
Drugs
samuraciclibelacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-503846-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503846-30-00.